Health care legislation firm Frier Levitt has analyzed FDA enforcement actions towards “research only” peptide distributors. Their conclusion: the FDA considers a product’s classification based on its meant use, not its disclaimers. When Web-sites incorporate dosage guides, reconstitution Guidance,